Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Atossa Therapeutics, Inc. ATOS

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
23.95
Revenue
0.04
Net Income
(37.71)
Free Cash Flow
(35.77)
Net Debt
(26.20)
Current Ratio
5.69
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
533.21
P/B ratio
0.80
Past 5Y EPS Growth
36.92%
This Y EPS Growth
4.95%
Next Y EPS Growth
34.24%
Next 5Y EPS Growth
58.12%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 88.57 71.19 41.41 26.20
Receivables — — — —
Inventory — — — 3.01
Other 1.49 2.10 3.08 —
92.22 74.46 45.62 31.01
2023 2024 2025 Q'26
Payables 0.81 0.68 4.29 1.98
ST’ Debt — — — —
Other 3.46 3.37 2.66 2.10
5.24 4.97 8.26 5.45
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — — ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (9.58) (9.64) — —
—
’25 (5.96) (7.26) (6.00) (10.54)
(29.76)
’24 (4.70) (4.53) (4.75) (7.05)
(21.03)
’23 (7.02) (4.46) (3.88) (5.57)
(20.94)
’22 (4.88) (5.95) (5.41) (4.52)
(20.76)
’21 (4.41) (5.34) (3.06) (3.66)
(16.47)
’20 (3.23) (2.23) (2.68) (3.43)
(11.57)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (9.58) (9.64) — —
—
’25 (5.97) (7.26) (6.01) (10.55)
(29.78)
’24 (4.70) (4.53) (4.76) (7.05)
(21.05)
’23 (7.02) (4.48) (3.88) (5.57)
(20.95)
’22 (4.89) (5.95) (5.42) (4.53)
(20.79)
’21 (4.41) (5.34) (3.07) (3.66)
(16.48)
’20 (3.23) (2.24) (2.68) (3.43)
(11.58)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (1.11) (0.95) — —
—
’25 (0.75) (1.05) (1.05) —
(4.04)
’24 (0.75) (0.75) (0.90) (0.75)
(3.00)
’23 (0.75) (1.20) (0.75) (0.90)
(3.60)
’22 (0.60) (0.75) (0.90) (0.90)
(3.15)
’21 (0.60) (0.90) (0.60) (0.60)
(2.70)
’20 (4.80) (6.45) (5.10) (13.34)
(29.53)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 7.50 8.25 11.55 8.25 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 27.00 20.85 34.65 19.35 — — —
High Price
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 11 10 13 14 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% — — — — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.96) (30.09) (25.50) (34.77) ‡‡‡‡‡ — —
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.96) (30.09) (25.50) (34.77) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.02 0.02 0.02 — — —
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.15) (3.60) (3.00) (4.04) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.46) (2.49) (2.51) (3.46) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.46) (2.49) (2.51) (3.46) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.97 10.82 8.52 4.57 ‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.45 8.41 8.39 8.61 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — — — — — — — — — — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.76) (20.94) (21.03) (29.76) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.03) (0.01) (0.02) (0.02) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.79) (20.95) (21.05) (29.78) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 112.63 86.98 69.49 37.36 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ — — — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (111.00) (88.57) (71.19) (41.41) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 117.96 91.02 71.48 39.35 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.36%) (27.39%) (29.54%) (56.06%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ (248.52%) (801.74%) (6,100.04%) 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.10%) (28.80%) (31.39%) (62.74%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Atossa Genetics Inc. (ATOS), a clinical-stage biotech chasing breast cancer innovations, exemplifies high-risk speculation with zero revenue to date and projections for a dramatic $54.5 million ramp in 2025. The company has suffered escalating losses—from $6.4 million in 2016 to $30.1 million in 2023—fueled by relentless cash burn ($21 million operating outflow in 2024) and explosive dilution, ballooning shares outstanding 51,000% to 126 million and eviscerating book value per share 96% to $0.57. Stock volatility tracks trial hype rather than fundamentals, with recent prices in the low single digits after an 88% plunge from 2024 peaks.

Amid the gloom, insiders signal confidence through recent purchases totaling ~16,900 shares, aligning with milestones for key asset (Z)-endoxifen, while Wall Street’s targets imply 730% to a staggering 2,757% upside from current levels. Projections hint at revenue ignition via FDA-cleared diagnostics and Phase 3 trials, potentially stabilizing per-share metrics post a projected 93% share haircut.

Yet red flags abound: persistent negative free cash flow, eroding equity, and a history of underdelivery in a sector with 90% trial failure rates. This contrarian analysis unmasks the hype versus harsh realities—will catalysts deliver, or will dilution and burn devour the working capital fortress?

Read full commentary →

Atossa Therapeutics, Inc. (ATOS) Latest News

News by impact score

Fine-tune

14 Aug

4 , 9:22 AM
Multiple catalysts converge for ATOS in 2H26. Multiple catalysts converging in 2H26 point to significant strategic and market shifts likely to alter company trajectory.

7 Aug

3 , 8:45 AM
Atossa Therapeutics reported second quarter 2026 financial results and issued a corporate update. Quarterly results and corporate updates can move near-term investor views and share price for small biotechs.

1 Jul

3 , 9:08 AM
Atossa Therapeutics raises up to $16.5 million in a registered direct offering. Registered direct offering supplies Atossa Therapeutics with additional capital to support its operations and development activities.

12 Jun

3 , 5:30 PM
Atossa Therapeutics closed a registered direct offering generating up to $16.5 million in gross proceeds. The capital infusion strengthens the balance sheet and extends operational runway without shifting core strategy or market position.

11 Jun

3 , 8:00 AM
Atossa Therapeutics announces registered direct offering of up to $16.5 million in gross proceeds. Registered direct offering supplies $16.5 million to fund operations and pipeline development.

10 Jun

4 Proactive, 12:51 PM
Atossa Therapeutics advances Endoxifen development targeting breast cancer treatment. Endoxifen progress signals major pipeline advancement likely to shift company trajectory and investor sentiment.

27 May

3 PR Newswire, 8:30 AM
Atossa Therapeutics announced ASCO 2026 abstracts demonstrating (Z)-Endoxifen activity across ESR1 mutations and progress in the ongoing EVANGELINE Phase 2 trial. Conference abstracts on clinical activity for a lead drug candidate can moderately lift near-term sentiment and visibility for a development-stage biotech.

14 May

4 , 8:30 AM
Atossa Therapeutics to host virtual KOL event featuring Dr. Laura Esserman discussing development of (Z)-Endoxifen in ER-positive breast cancer. KOL event with leading breast cancer expert on (Z)-Endoxifen development highlights key pipeline progress, likely driving significant investor sentiment and market performance.

13 May

4 Zacks Small Cap Research, 3:00 AM
Analyst initiates coverage on Atossa Therapeutics (ATOS), highlighting Endoxifen’s expanding opportunities from oncology treatments to orphan diseases. Analyst coverage initiation spotlights Endoxifen's pipeline expansion into orphan diseases, poised to significantly enhance ATOS's market position and investor sentiment.

8 May

3 PR Newswire, 8:45 AM
Atossa Therapeutics reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results with corporate update moderately influence financial performance and investor sentiment without transformative changes.

6 May

4 PR Newswire, 8:30 AM
Atossa Therapeutics announced publication of KARISMA Endoxifen Trial results, demonstrating significant reduction in mammographic breast density in healthy premenopausal women. Positive Phase 2 trial data on Endoxifen for breast density reduction advances Atossa's pipeline toward breast cancer prevention, likely enhancing investor sentiment and market performance.

4 May

4 PR Newswire, 8:30 AM
Atossa Therapeutics received FDA Rare Pediatric Disease Designation for (Z)-Endoxifen to treat McCune-Albright Syndrome, a rare disorder causing fibrous dysplasia of bone, precocious puberty, and other endocrine issues. FDA Rare Pediatric Disease Designation grants priority review vouchers and expedited development incentives, significantly advancing ATOS's pipeline and boosting investor sentiment.

31 Mar

4 GlobeNewswire, 7:00 AM
Atossa Genetics Inc. (ATOS) advances AI-ready digital transformation by adopting Lumen's Network as a Service. AI-ready infrastructure from Lumen enables major strategic upgrades in ATOS's digital capabilities, likely boosting innovation and investor sentiment.

25 Mar

3 PR Newswire, 5:30 PM
Atossa Therapeutics reported fourth quarter and year-end 2025 financial results and provided a corporate update. Quarterly and annual financial results with corporate update influence financial performance and market sentiment moderately.

19 Mar

3 PR Newswire, 8:00 AM
Atossa Therapeutics bolsters its clinical leadership team by appointing two experienced biopharma executives: Dr. Jonathan W. Berlin as Chief Medical Officer and Dr. Sherry A. Chowdhury as Senior VP of Clinical Development. Adding seasoned clinical executives strengthens pipeline execution and competitive positioning in biopharma development.

12 Mar

3 PR Newswire, 8:00 AM
Atossa Therapeutics presented a clinical trial update highlighting (Z)-Endoxifen research at the 2026 MDA Clinical & Scientific Conference. Clinical trial update on key (Z)-Endoxifen program at a scientific conference enhances visibility and sentiment around product development.

11 Feb

4 PR Newswire, 8:30 AM
Atossa Therapeutics highlighted its accomplishments in 2025 and outlined its outlook for 2026 in a letter to shareholders. The company emphasized key developments and strategic initiatives aimed at enhancing its market position and advancing its product pipeline. Shareholders were informed about the progress made over the past year and the anticipated goals for the upcoming year, reflecting a commitment to growth and innovation in the biotechnology sector. The outlined strategic initiatives and accomplishments are likely to significantly impact Atossa's future performance and investor sentiment.

9 Feb

3 Simply Wall St., 8:44 AM
Atossa Genetics Inc. is urged to approach its business growth cautiously as it navigates challenges in the competitive landscape. The company must focus on strategic initiatives to enhance its market position while managing risks associated with its operations and product development. Stakeholders are advised to monitor the company's progress closely to assess its long-term viability and potential for success. Cautious growth strategies may moderately influence Atossa's financial performance and competitive positioning.

5 Feb

4 PR Newswire, 8:30 AM
Atossa Genetics Inc. maintains a strong market position for (Z)-Endoxifen in treating Duchenne Muscular Dystrophy following the reauthorization of the Priority Review Voucher Program by Congress. This program is crucial for expediting the review process of new drugs, potentially enhancing Atossa's competitive edge in the market. The reauthorization of the Priority Review Voucher Program is likely to significantly impact Atossa's strategic positioning and market opportunities.

21 Jan

3 , 9:05 AM
Steven Quay, M.D., Ph.D., the Founder and CEO of Atossa Therapeutics, has been recognized as one of the Top 50 Healthcare Technology CEOs of 2025. This accolade highlights his leadership and contributions to the healthcare technology sector, positioning Atossa Genetics Inc. favorably within the industry. Recognition of leadership in healthcare technology may enhance investor sentiment and brand positioning.

16 Jan

4 PR Newswire, 4:40 PM
Atossa Genetics Inc. has received FDA Orphan Drug Designation for (Z)-Endoxifen, a treatment aimed at Duchenne Muscular Dystrophy (DMD). This designation is intended to facilitate the development of therapies for rare diseases, providing Atossa with potential benefits such as tax incentives and market exclusivity upon approval. The company is focused on advancing its clinical programs for DMD, which is a severe genetic disorder characterized by progressive muscle degeneration. Receiving FDA Orphan Drug Designation is a significant regulatory milestone that can enhance Atossa's strategic position and market potential in treating DMD.

6 Jan

4 PR NewswireMT NewswiresMT NewswiresSimply Wall St.Clinical Trials ArenaMT NewswiresMT NewswiresZacks, 8:15 AM
Atossa Therapeutics has received a 'Study May Proceed' letter from the FDA for its investigational new drug application for (Z)-Endoxifen, aimed at treating metastatic breast cancer. This approval allows the company to advance its clinical studies for this treatment, which could potentially address unmet medical needs in breast cancer therapy. FDA approval for clinical studies is a significant step that could enhance Atossa's product pipeline and market position.

17 Dec

4 , 8:15 AM
Atossa Therapeutics has been awarded the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category, recognizing its advancements in targeted therapies for breast cancer. This accolade highlights the company's commitment to innovation and excellence in clinical research, potentially enhancing its reputation and market position. Winning a prestigious award in precision therapy can significantly boost Atossa's credibility and investor interest, impacting its future performance.

15 Dec

4 PR NewswireSimply Wall St.MT NewswiresMotley FoolMotley FoolMT NewswiresMT NewswiresClinical Trials Arena, 8:00 AM
Atossa Therapeutics presented four clinical trial updates on (Z)-Endoxifen research at the 2025 San Antonio Breast Cancer Symposium, highlighting advancements in its development for breast cancer treatment. The updates included data on safety, efficacy, and potential market applications, showcasing the company's commitment to innovative therapies in oncology. The presentation of significant clinical trial updates indicates a major strategic move that could enhance Atossa's competitive positioning in the oncology market.

11 Dec

4 PR Newswire, 8:00 AM
Atossa Therapeutics has received FDA Rare Pediatric Disease Designation for its drug (Z)-Endoxifen, aimed at treating Duchenne Muscular Dystrophy (DMD). This designation is significant as it may expedite the development and review process for the drug, potentially leading to faster access for patients suffering from this severe condition. The designation underscores Atossa's commitment to addressing unmet medical needs in pediatric populations. The FDA designation could significantly enhance Atossa's strategic positioning and market opportunities in the pediatric therapeutic space.

9 Dec

4 PR Newswire, 8:00 AM
Atossa Therapeutics has announced the issuance of a U.S. patent for enteric oral (Z)-Endoxifen formulations and methods for treating patients with this compound. This patent is expected to enhance the company's intellectual property portfolio and support its ongoing development efforts in breast cancer treatment. The patent issuance represents a significant strategic move that could enhance Atossa's competitive position and investor sentiment.

4 Dec

4 PR Newswire, 8:00 AM
Atossa Genetics Inc. has outlined an accelerated FDA strategy for (Z)-Endoxifen, aimed at advancing its development across the breast cancer continuum. This initiative is part of the company's efforts to enhance treatment options for patients and potentially expedite the drug's market entry. The strategy includes a focus on various stages of breast cancer, indicating a comprehensive approach to addressing this significant health issue. The accelerated FDA strategy for (Z)-Endoxifen could significantly impact Atossa's market position and investor sentiment.

2 Dec

4 PR Newswire, 8:00 AM
Insilico Medicine and Atossa Therapeutics have published a study in Nature Scientific Reports that identifies (Z)-Endoxifen as a potential therapeutic candidate for glioblastoma. The research utilizes artificial intelligence to analyze the compound's efficacy, suggesting it may offer new treatment options for this aggressive form of brain cancer. The identification of (Z)-Endoxifen as a potential treatment for glioblastoma could significantly enhance Atossa's product pipeline and market positioning.

17 Nov

4 , 9:07 AM
Atossa Genetics Inc. highlights the potential of (Z)-Endoxifen for treating Duchenne Muscular Dystrophy (DMD), particularly in symptomatic female carriers, following a peer-reviewed publication and a scientific presentation. The company aims to leverage this emerging opportunity to address unmet medical needs in DMD, which could expand its therapeutic portfolio and market reach. The focus on (Z)-Endoxifen for DMD represents a significant strategic move that could enhance Atossa's market position and investor sentiment.

12 Nov

3 PR NewswireMotley FoolMotley FoolGuruFocus.comGuruFocus.comGuruFocus.com, 8:15 AM
Atossa Genetics Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its ongoing projects. The company provided updates on its clinical trials and strategic initiatives aimed at advancing its product pipeline. Management expressed optimism about future growth and outlined plans for upcoming milestones. The financial results and updates on clinical trials indicate a moderate influence on the company's future performance and market sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us